ReviewThe oncologist2013
Perspectives on treatment of metastatic castration-resistant prostate cancer.
Review in The oncologist, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03103724 (A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial.Health and quality of life outcomes · 2017Trial
- Enzalutamide in European and North American men participating in the AFFIRM trial.BJU international · 2015Trial
- The Transcription Axes ERK-Elk1, JNK-cJun, and JAK-STAT Promote Autophagy Activation and Proteasome Inhibitor Resistance in Prostate Cancer Cells.Current issues in molecular biology · 2025Article
- High Mobility Group AT-hook 2: A Biomarker Associated with Resistance to Enzalutamide in Prostate Cancer Cells.Cancers · 2024Article
- Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against enzalutamide.PloS one · 2023Observational
- MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.British journal of cancer · 2022Article
- Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases.Bone research · 2021Article
- Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133high/CD44high prostate cancer stem cells.Molecular biology reports · 2021Article
- Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews.The patient · 2019Article
- Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings.The patient · 2017Article
- An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.Advances in therapy · 2016Review
- Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.Oncotarget · 2016Article
- Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.International journal of oncology · 2016Article
- Prostate Cancer Stem Cells: Research Advances.International journal of molecular sciences · 2015Review
- An update on enzalutamide in the treatment of prostate cancer.Therapeutic advances in urology · 2015Review
- Biological characteristics of prostate cancer cells are regulated by hypoxia-inducible factor 1αOncology letters · 2014Article
- In reply.The oncologist · 2014Article
- Resistance to "castration-resistant".The oncologist · 2014Article
- [Personalized urooncology based on molecular uropathology: what is the future?].Der Urologe. Ausg. A · 2013Article
Corrections and comments
- Commented on by
- Commented on byIn reply.2014
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The arrival of several new agents--cabazitaxel, abiraterone acetate, enzalutamide, and radium-223--is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.